enGene (NASDAQ:ENGN) Now Covered by Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of enGene (NASDAQ:ENGN) in a research report released on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $25.00 price objective on the stock.

Several other equities analysts have also commented on ENGN. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Morgan Stanley restated an “overweight” rating and issued a $40.00 target price on shares of enGene in a research report on Wednesday, September 11th. Oppenheimer restated an “outperform” rating and issued a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. JMP Securities reiterated a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research report on Friday, December 6th. Finally, Raymond James began coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price on the stock. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, enGene has an average rating of “Buy” and a consensus price target of $29.78.

enGene Stock Performance

Shares of ENGN stock opened at $5.96 on Monday. The company has a market cap of $263.53 million, a P/E ratio of -10.28 and a beta of -0.78. The business has a 50 day moving average of $8.13 and a two-hundred day moving average of $7.80. enGene has a 52 week low of $4.42 and a 52 week high of $18.40. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. As a group, analysts anticipate that enGene will post -1.52 EPS for the current year.

Insider Activity

In other enGene news, CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average cost of $5.70 per share, with a total value of $57,000.00. Following the completion of the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $57,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Growth Opportunities F. Forbion bought 41,639 shares of enGene stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $5.97 per share, with a total value of $248,584.83. Following the completion of the acquisition, the insider now directly owns 2,059,459 shares of the company’s stock, valued at $12,294,970.23. This represents a 2.06 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 420,965 shares of company stock worth $2,651,103. 13.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On enGene

A number of institutional investors and hedge funds have recently modified their holdings of ENGN. SR One Capital Management LP acquired a new position in shares of enGene in the 2nd quarter worth $4,715,000. Franklin Resources Inc. increased its stake in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after buying an additional 619,100 shares during the period. Logos Global Management LP lifted its stake in enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares in the last quarter. Finally, Wolverine Asset Management LLC acquired a new position in shares of enGene in the third quarter worth about $37,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.